Clinical Characterization and Underlying Pathophysiological Mechanisms in Atopic Dermatitis: A Comprehensive Exploration of its Clinical Presentation and Emerging Therapeutic Perspectives

Main Article Content

Brisa Arlin Gómez Arteaga
Mariel Muñoz Rodriguez
Samantha Castro Cortés
Karla Itzel Sánchez Gutiérrez
Gabriela Cipactli Garcia Alvarez

Abstract

Atopic dermatitis, a chronic inflammatory skin disease of a predominantly genetic nature, has attracted continued interest in the field of dermatology and immunology due to its pathophysiological complexity and its significant impact on patients' quality of life. In this article, we present a comprehensive review of the current literature on atopic dermatitis, addressing its clinical characterization from a holistic perspective and the underlying pathophysiologic mechanisms that define it.


From a clinical point of view, the heterogeneity of cutaneous manifestations in atopic dermatitis is highlighted, including erythema, intense pruritus, lichenification and exudation. In addition, the variability of clinical presentations throughout the different stages of life is explored, focusing on early childhood and adulthood, which underlines the need for a multidisciplinary and personalized approach to its management.


In terms of pathophysiological mechanisms, the dysfunction of the skin barrier, the dysregulated immune response and the involvement of key cytokines in the perpetuation of the inflammatory process are examined in detail. The interaction between genetic and environmental factors in the development and exacerbation of the disease is discussed, as well as the connection between atopic dermatitis and other atopic conditions, such as asthma and allergic rhinitis.


In addition, conventional and emerging therapies for atopic dermatitis, including topical corticosteroids, calcineurin inhibitors, biologic therapies, and approaches aimed at modulating the skin microbiota, are discussed. The importance of patient education, skin care strategies and a comprehensive approach to achieve effective symptom control and prevent recurrences is emphasized.


In summary, this article provides a comprehensive view of atopic dermatitis, merging its clinical and pathophysiological aspects. Advanced understanding of the clinical diversity and underlying mechanisms is crucial for an informed and optimal management of this constantly evolving chronic skin condition.

Article Details

How to Cite
Brisa Arlin Gómez Arteaga, Mariel Muñoz Rodriguez, Samantha Castro Cortés, Karla Itzel Sánchez Gutiérrez, & Gabriela Cipactli Garcia Alvarez. (2023). Clinical Characterization and Underlying Pathophysiological Mechanisms in Atopic Dermatitis: A Comprehensive Exploration of its Clinical Presentation and Emerging Therapeutic Perspectives. International Journal of Medical Science and Clinical Research Studies, 3(10), 2156–2160. https://doi.org/10.47191/ijmscrs/v3-i10-06
Section
Articles

References

I. Martín Mateos. Guide to the treatment of atopic dermatitis in the child. 2nd edition. Expert Group Consensus Document. Madrid: Ergon; 2011.

II. Thomsen SF, Elmose C, Szecsi PB, Stender S, Kyvik KO, Backer V, Thyssen JP. Filaggrin gene lossof-function mutations explain discordance of atopic dermatitis within dizygotic twin pairs. In J Dermatol. 2016;55(12):1341-4.

III. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66:8-16.

IV. Escarrer M, Valderrama S. Atopic dermatitis. A treatise on allergology. Madrid: Ergon; 2019.

V. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70:338-51.

VI. Kim JP, Chao LX, Simpson EL, Silverberg JL. Persistence of atopic dermatitis (AD): a systematic review and meta-analysis. Am Acad Dermatol. 2016;75(4):681-7.

VII. Ridao M. Atopic dermatitis. Pediatr Integral. 2012;XVI(3):213-21.

VIII. Nankervis H, Pynn EV, Boyle RJ, Rushton L, Williams HC, Hewson DM, et al. House dust mite reduction and avoidance measures for treating eczema. Cochrane Database Syst Rev. 2015;1:CD008426.

IX. Martorell Aragonés A, Martorell Calatayud A. Attitude towards the child affected by atopic dermatitis. Protoc diagn ter pediatr. 2013;1:25-36.

X. Van Bever H, Nagarajan S, Shek L, Lee B. Primary prevention of allergy. Will it son become a reality? Pediatr Allergy Immunol. 2016;27:6-12.

XI. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71:116-132.

XII. Wollenberg A, Oranje A, Deleuran M, Simon D, Szalai Z, Kunz B, et al. European Task Force on Atopic Dermatitis/EADV Eczema Task Force. ETFAD/ EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol. 2016 May;30(5):729-47.

XIII. Ferreira S, Torres T. Dupilumab for the treatment of atopic dermatitis. Actas Dermosifilogr. 2018; 109(3):13-22.

XIV. Mastrorilli C, Caffarelli C, Hoffmann-Sommergruber. Food allergy and atopic dermatitis: prediction, progression, and prevention. Pediatr Allergy Immunol. 2017;28(8):831-40.

Most read articles by the same author(s)